Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Obesity

PUBLISHER: Visiongain | PRODUCT CODE: 1936016

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 1936016

Anti-obesity Drugs Market Report 2026-2036

PUBLISHED:
PAGES: 400 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 6090
PDF (Team License - Up to 6 Users)
USD 7210
PDF (Site License)
USD 8470
PDF (Enterprise License - Includes Free Datasets)
USD 10703

Add to Cart

Description

Table of Contents

List of Tables

The global Anti-obesity Drugs market 2026-2036 is projected to grow at a CAGR of 24.2% by 2036.

The Anti-obesity Drugs Market Report 2026-2036 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Digital Healthcare Integration Strengthens Demand for Pharmacological Obesity Management

The anti-obesity drugs market is gaining structural momentum as the rapid expansion of digital health ecosystems strengthens patient access to, and engagement with, pharmacological obesity management. India's Ayushman Bharat Digital Mission illustrates this shift, with more than 76 crore (760 million) Ayushman Bharat Health Accounts (ABHA) created and over 52 crore (520 million) health records linked as of April 2025. This rapidly expanding digital backbone is improving continuity of care, increasing disease awareness, and embedding drug therapy more firmly within structured obesity management pathways.

Telemedicine platforms and mobile health applications are enabling routine physician interaction, remote consultations, and structured follow-up, allowing patients to monitor weight, dietary patterns, and treatment adherence more effectively. The integration of wearable devices with digital platforms supports ongoing tracking of key health indicators, aligning lifestyle interventions with prescribed drug regimens. For clinicians, real-time access to patient data enables closer supervision, timely dose optimisation, and earlier identification of adverse effects, supporting sustained pharmacological intervention.

Digital channels are also expanding the reach of obesity treatment beyond urban centres. In semi-urban and rural regions, where specialist infrastructure remains constrained, virtual consultations and e-prescriptions are improving access to anti-obesity medicines. Online pharmacies and digitally enabled distribution models are reducing logistical barriers, while integrated health records support coordinated care across physicians, specialists, and nutrition professionals. Improved convenience and treatment continuity are translating into higher compliance rates and lower therapy drop-off. As confidence in digital healthcare delivery grows, digital infrastructure is emerging as a durable demand driver, reshaping how anti-obesity drug therapies are accessed, monitored, and sustained.

Stringent Regulatory Requirements Elevate Development Costs and Market Entry Barriers

The anti-obesity drugs market faces sustained regulatory pressure, as stringent approval frameworks significantly increase compliance costs and lengthen development timelines. Regulators across major markets require extensive clinical evidence, detailed documentation, and strict adherence to Good Clinical Practice (GCP) standards, demanding substantial financial and technical resources from drug developers. Prolonged review periods delay market entry, directly affecting revenue visibility and return on investment, while continuously evolving regulatory expectations add operational complexity through ongoing compliance monitoring and post-approval obligations. These dynamics disproportionately impact smaller companies and emerging biotechs, for whom regulatory expenditure represents a major barrier to entry.

In the United States, the Food and Drug Administration mandates comprehensive safety assessments for chronic weight-management therapies, including compulsory cardiovascular outcome trials (CVOTs). These requirements were formalised following historical safety concerns associated with earlier obesity drugs such as sibutramine and fenfluramine. CVOTs typically involve large patient cohorts monitored over multiple years, materially increasing trial duration and development costs. Similarly, the European Medicines Agency applies rigorous long-term benefit-risk evaluations and has previously delayed or declined obesity drug approvals where cardiovascular or psychiatric safety data were insufficient, as seen in the initial review of naltrexone/bupropion. In Japan, the Pharmaceuticals and Medical Devices Agency requires population-specific clinical data, often necessitating additional regional trials and further delaying commercialisation.

In India, regulatory constraints also present a meaningful cost burden. Under the Drugs Rules, 1945, as amended in 2024, applicants must pay a fee of US$5,000 for the import of new drugs, alongside meeting Central Drugs Standard Control Organization (CDSCO) requirements for extensive clinical evaluation. Approvals for therapies such as semaglutide and tirzepatide involved comprehensive safety and efficacy studies, including assessments of cardiovascular and metabolic outcomes, significantly increasing research and development expenditure. While these regulatory standards reinforce patient safety, drug quality, and public health protection, they also raise compliance costs, restrict pricing flexibility, and limit the pace of innovation within the anti-obesity drug development landscape.

What would be the Impact of US Trade Tariffs on the Global Anti-obesity Drugs Market?

Proposed changes to US trade policy could introduce material cost and supply-chain risks for the global anti-obesity drugs market. For the anti-obesity drugs segment, the implications could be significant. Branded and patented therapies, which already command premium pricing in the US market, may face further cost escalation, constraining patient access and reimbursement flexibility. In parallel, the industry's reliance on globally distributed supply chains-particularly for active pharmaceutical ingredients sourced from countries such as China-adds an additional layer of vulnerability should tariffs expand beyond finished products. Rising input costs and pricing pressure could dampen near-term profitability and weaken incentives for sustained investment in research and development.

At the same time, the policy environment may accelerate strategic realignment. Indian pharmaceutical manufacturers are likely to intensify market diversification efforts, expanding their presence across Europe, emerging markets, and other non-US regions to mitigate exposure to US trade risk. Multinational companies may also reassess manufacturing footprints, contract manufacturing strategies, and localisation investments. Overall, potential US trade tariffs are expected to influence cost structures, supply-chain configuration, and long-term innovation strategies across the global anti-obesity drugs market, reinforcing policy risk as a meaningful variable in future market planning.

What Questions Should You Ask before Buying a Market Research Report?

  • How is Anti-obesity Drugs Market evolving?
  • What is driving and restraining Anti-Obesity Drugs Market?
  • How will each Anti-Obesity Drugs Market submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2036?
  • How will the market shares for each Anti-obesity Drugs Market submarket develop from 2026 to 2036?
  • What will be the main driver for the overall market from 2026 to 2036?
  • Will leading Anti-obesity Drugs Market markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2036 and which geographical region will lead the market in 2036?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Anti-Obesity Drugs Market projects for these leading companies?
  • How will the industry evolve during the period between 2026 and 2036? What are the implications of Anti-obesity Drugs
  • Market projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale Anti-obesity Drugs Market ?
  • Where is Anti-obesity Drugs Market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact Anti-obesity Drugs Market today, and over the next 10 years:

  • Our 400+ pages report provides 162 tables and 233 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
  • Forecasts to 2036 and other analysis reveal commercial prospects
  • In addition to revenue forecasting to 2036, our new study provides you with recent results, growth rates, and market shares.
  • You will find original analysis, with business outlooks and developments.
  • Discover qualitative analysis (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Anti-Obesity Drugs Market prices and recent developments.

Segments Covered in the Report

  • Drug Type
  • Prescription
  • OTC
  • Molecule Type
  • Biologics
  • Small Molecules
  • Type of Agonist
  • Single-Agonist
  • Dual-Agonist
  • Tri-Agonist
  • Action Pathway
  • Centrally Acting
  • Peripherally Acting
  • Combined (Centrally and Peripherally Acting)
  • Route of Administration
  • Oral
  • Intravenous
  • Subcutaneous
  • Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 25 leading national markets:

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Denmark
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • South East Asia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • MEA
  • GCC
  • South Africa
  • Rest of MEA

The report also includes profiles and for some of the leading companies in the Anti-obesity Drugs Market, 2026 to 2036, with a focus on this segment of these companies' operations.

  • Leading companies profiled in the report
  • Altimmune
  • Amgen Inc.
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • CHEPLAPHARM Arzneimittel GmbH
  • Structure Therapeutics, Inc.
  • Currax
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • ZEALAND PHARMA
  • Zydus Group

Overall world revenue for Anti-obesity Drugs Market, 2026 to 2036 in terms of value the market will surpass US$ 22.0 billion in 2026, our work calculates. We predict strong revenue growth through to 2036. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

  • How will the Anti-obesity Drugs Market, 2026 to 2036 report help you?
  • In summary, our 400+ page report provides you with the following knowledge:
  • Revenue forecasts to 2036 for Anti-obesity Drugs Market, 2026 to 2036, with forecasts for drug type, Molecule Type, Type of Agonist, by Action Pathway, Route of Administration and Distribution Channel each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2036 for five regional and 27 key national markets - See forecasts for the Anti-obesity Drugs Market, 2026 to 2036 in North America, Europe, Asia Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 19 of the major companies involved in the Anti-obesity Drugs Market, 2026 to 2036.
  • Find quantitative and qualitative analysis with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Show more
Product Code: PHA1380

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to Anti-obesity Drugs Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Rising global obesity prevalence increases demand for innovative anti-obesity drugs.
      • 3.3.1.2 Expanding chronic disease awareness drives patients toward medical weight management solutions.
      • 3.3.1.3 Launch of advanced, safer drugs boosts adoption and commercial market growth.
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 High pricing of prescription anti-obesity drugs limits widespread patient adoption globally.
      • 3.3.2.2 Safety concerns and adverse effects reduce long-term therapy adherence rates.
      • 3.3.2.3 Stringent regulatory approvals delay the commercialization of new pharmacological interventions worldwide.
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Emerging economies present high revenue potential due to rising healthcare investments.
      • 3.3.3.2 Growing geriatric population creates demand for specialized obesity management medications.
      • 3.3.3.3 Digital health integration enables personalized obesity treatment, increasing market penetration.
  • 3.4 U.S. Tariffs: What's the Impact on Global Anti-obesity Drugs Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
      • 3.4.2.1 Why V-Shaped Recovery?
      • 3.4.2.2 Impact from Tariffs
      • 3.4.2.3 Market Dynamics and Demand Recovery
      • 3.4.2.4 Policy and Funding Support
      • 3.4.2.5 Timeframe for Recovery
    • 3.4.3 U-Shaped Recovery Scenario
      • 3.4.3.1 Why U-Shaped Recovery?
      • 3.4.3.2 Impact from Tariffs
      • 3.4.3.3 Market Dynamics and Demand Recovery
      • 3.4.3.4 Policy and Funding Support
      • 3.4.3.5 Timeframe for Recovery
    • 3.4.4 L Shaped Recovery Scenario
      • 3.4.4.1 Why L-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
      • 3.4.4.5 Timeframe for Recovery
    • 3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2025-2030) and Long-term (2025-2035) Planning?
    • 3.4.6 Impact of U.S. and China Trade War on Anti-obesity Drugs Market
    • 3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
    • 3.4.8 Global Market Tariff Sensitivity and Margin Pressure Analysis
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis

4 Anti-obesity Drugs Market Analysis by Drug Type

  • 4.1 Key Findings
  • 4.2 Drug Type Segment: Market Attractiveness Index
  • 4.3 Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 4.4 Prescription
    • 4.4.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)
  • 4.5 OTC
    • 4.5.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 4.5.2 Market Share by Region, 2026 & 2036 (%)

5 Anti-obesity Drugs Market Analysis by Molecule Type

  • 5.1 Key Findings
  • 5.2 Molecule Type Segment: Market Attractiveness Index
  • 5.3 Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
  • 5.4 Biologics
    • 5.4.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 Small Molecules
    • 5.5.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)

6 Anti-obesity Drugs Market Analysis by Type of Agonist

  • 6.1 Key Findings
  • 6.2 Type of Agonist Segment: Market Attractiveness Index
  • 6.3 Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
  • 6.4 Single-Agonist
    • 6.4.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Dual-Agonist
    • 6.5.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)
  • 6.6 Tri-Agonist
    • 6.6.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 6.6.2 Market Share by Region, 2026 & 2036 (%)

7 Anti-obesity Drugs Market Analysis by Action Pathway

  • 7.1 Key Findings
  • 7.2 Action Pathway Segment: Market Attractiveness Index
  • 7.3 Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
  • 7.4 Centrally Acting
    • 7.4.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)
  • 7.5 Peripherally Acting
    • 7.5.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 7.5.2 Market Share by Region, 2026 & 2036 (%)
  • 7.6 Combined (Centrally and Peripherally Acting)
    • 7.6.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 7.6.2 Market Share by Region, 2026 & 2036 (%)

8 Anti-obesity Drugs Market Analysis by Route of Administration

  • 8.1 Key Findings
  • 8.2 Route of Administration Segment: Market Attractiveness Index
  • 8.3 Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 8.4 Oral
    • 8.4.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 8.4.2 Market Share by Region, 2026 & 2036 (%)
  • 8.5 Intravenous
    • 8.5.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 8.5.2 Market Share by Region, 2026 & 2036 (%)
  • 8.6 Subcutaneous
    • 8.6.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 8.6.2 Market Share by Region, 2026 & 2036 (%)

9 Anti-obesity Drugs Market Analysis by Distribution Channel

  • 9.1 Key Findings
  • 9.2 Distribution Channel Segment: Market Attractiveness Index
  • 9.3 Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 9.4 Hospital Pharmacies
    • 9.4.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 9.4.2 Market Share by Region, 2026 & 2036 (%)
  • 9.5 Retail Pharmacies
    • 9.5.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 9.5.2 Market Share by Region, 2026 & 2036 (%)
  • 9.6 Online Pharmacies
    • 9.6.1 Market Size by Region, 2026-2036 (US$ Billion)
    • 9.6.2 Market Share by Region, 2026 & 2036 (%)

10 Anti-obesity Drugs Market Analysis by Region

  • 10.1 Key Findings
  • 10.2 Regional Market Size Estimation and Forecast

11 North America Anti-obesity Drugs Market Analysis

  • 11.1 Key Findings
  • 11.2 North America Anti-obesity Drugs Market Attractiveness Index
  • 11.3 North America Anti-obesity Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 11.4 North America Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 11.5 North America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 11.6 North America Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
  • 11.7 North America Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
  • 11.8 North America Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
  • 11.9 North America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 11.10 North America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 11.11 U.S. Anti-obesity Drugs Market Analysis
  • 11.12 Canada Anti-obesity Drugs Market Analysis

12 Europe Anti-obesity Drugs Market Analysis

  • 12.1 Key Findings
  • 12.2 Europe Anti-obesity Drugs Market Attractiveness Index
  • 12.3 Europe Anti-obesity Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 12.4 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 12.5 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 12.6 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
  • 12.7 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
  • 12.8 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
  • 12.9 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 12.10 Europe Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 12.11 Germany Anti-obesity Drugs Market Analysis
  • 12.12 France Anti-obesity Drugs Market Analysis
  • 12.13 UK Anti-obesity Drugs Market Analysis
  • 12.14 Italy Anti-obesity Drugs Market Analysis
  • 12.15 Spain Anti-obesity Drugs Market Analysis
  • 12.16 Russia Anti-obesity Drugs Market Analysis
  • 12.17 Rest of Europe Anti-obesity Drugs Market Analysis

13 Asia Pacific Anti-obesity Drugs Market Analysis

  • 13.1 Key Findings
  • 13.2 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
  • 13.3 Asia Pacific Anti-obesity Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 13.4 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 13.5 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 13.6 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
  • 13.7 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
  • 13.8 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
  • 13.9 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 13.10 Asia Pacific Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 13.11 Japan Anti-obesity Drugs Market Analysis
  • 13.12 China Anti-obesity Drugs Market Analysis
  • 13.13 India Anti-obesity Drugs Market Analysis
  • 13.14 Australia Anti-obesity Drugs Market Analysis
  • 13.15 South Korea Anti-obesity Drugs Market Analysis
  • 13.16 Singapore Anti-obesity Drugs Market Analysis
  • 13.17 Rest of Asia Pacific Anti-obesity Drugs Market Analysis

14 Latin America Anti-obesity Drugs Market Analysis

  • 14.1 Key Findings
  • 14.2 Latin America Anti-obesity Drugs Market Attractiveness Index
  • 14.3 Latin America Anti-obesity Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 14.4 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 14.5 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 14.6 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
  • 14.7 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
  • 14.8 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
  • 14.9 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 14.10 Latin America Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 14.11 Brazil Anti-obesity Drugs Market Analysis
  • 14.12 Mexico Anti-obesity Drugs Market Analysis
  • 14.13 Argentina Anti-obesity Drugs Market Analysis
  • 14.14 Rest of Latin America Anti-obesity Drugs Market Analysis

15 Middle East & Africa Anti-obesity Drugs Market Analysis

  • 15.1 Key Findings
  • 15.2 Middle East & Africa Anti-obesity Drugs Market Attractiveness Index
  • 15.3 Middle East & Africa Anti-obesity Drugs Market by Country, 2026, 2031 & 2036 (US$ Billion)
  • 15.4 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Country
  • 15.5 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Drug Type
  • 15.6 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Molecule Type
  • 15.7 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Type of Agonist
  • 15.8 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Action Pathway
  • 15.9 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Route of Administration
  • 15.10 Middle East & Africa Anti-obesity Drugs Market Size Estimation and Forecast by Distribution Channel
  • 15.11 GCC Anti-obesity Drugs Market Analysis
  • 15.12 South Africa Anti-obesity Drugs Market Analysis
  • 15.13 Rest of MEA Anti-obesity Drugs Market Analysis

16 Company Profiles

  • 16.1 Competitive Landscape, 2026
  • 16.2 Strategic Outlook
  • 16.3 Amgen Inc.
    • 16.3.1 Company Snapshot
    • 16.3.2 Company Overview
    • 16.3.3 Financial Analysis
      • 16.3.3.1 Net Revenue, 2021-2024
      • 16.3.3.2 R&D, 2021-2024
      • 16.3.3.3 Regional Market Shares, 2024
    • 16.3.4 Product Benchmarking
    • 16.3.5 SWOT Analysis
    • 16.3.6 Strategic Outlook
  • 16.4 AstraZeneca
    • 16.4.1 Company Snapshot
    • 16.4.2 Company Overview
    • 16.4.3 Financial Analysis
      • 16.4.3.1 Net Revenue, 2021-2024
      • 16.4.3.2 R&D, 2021-2024
      • 16.4.3.3 Regional Market Shares, 2024
      • 16.4.3.4 Business Segment Market Shares, 2024
    • 16.4.4 Product Benchmarking
    • 16.4.5 SWOT Analysis
    • 16.4.6 Strategic Outlook
  • 16.5 Altimmune, Inc
    • 16.5.1 Company Snapshot
    • 16.5.2 Company Overview
    • 16.5.3 Financial Analysis
      • 16.5.3.1 Net Revenue, 2021-2024
      • 16.5.3.2 R&D, 2021-2024
    • 16.5.4 Product Benchmarking
    • 16.5.5 SWOT Analysis
    • 16.5.6 Strategic Outlook
  • 16.6 Bayer AG
    • 16.6.1 Company Snapshot
    • 16.6.2 Company Overview
    • 16.6.3 Financial Analysis
      • 16.6.3.1 Net Revenue, 2021-2024
      • 16.6.3.2 R&D, 2021-2024
      • 16.6.3.3 Regional Market Shares, 2024
      • 16.6.3.4 Business Segment Market Shares, 2024
    • 16.6.4 Product Benchmarking
    • 16.6.5 SWOT Analysis
    • 16.6.6 Strategic Outlook
  • 16.7 Boehringer Ingelheim International GmbH
    • 16.7.1 Company Snapshot
    • 16.7.2 Company Overview
    • 16.7.3 Financial Analysis
      • 16.7.3.1 Net Revenue, 2021-2024
      • 16.7.3.2 R&D, 2021-2024
      • 16.7.3.3 Regional Market Shares, 2024
      • 16.7.3.4 Business Segment Market Shares, 2024
    • 16.7.4 Product Benchmarking
    • 16.7.5 SWOT Analysis
    • 16.7.6 Strategic Outlook
  • 16.8 CHEPLAPHARM Arzneimittel GmbH
    • 16.8.1 Company Snapshot
    • 16.8.2 Company Overview
    • 16.8.3 Product Benchmarking
    • 16.8.4 SWOT Analysis
    • 16.8.5 Strategic Outlook
  • 16.9 Curaxx Pharmaceuticals LLC
    • 16.9.1 Company Snapshot
    • 16.9.2 Company Overview
    • 16.9.3 Product Benchmarking
    • 16.9.4 SWOT Analysis
    • 16.9.5 Strategic Outlook
  • 16.10 Eisai Co., Ltd.
    • 16.10.1 Company Snapshot
    • 16.10.2 Company Overview
    • 16.10.3 Financial Analysis
      • 16.10.3.1 Net Revenue, 2021-2024
      • 16.10.3.2 Regional Market Shares, 2024
    • 16.10.4 Product Benchmarking
    • 16.10.5 SWOT Analysis
    • 16.10.6 Strategic Outlook
  • 16.11 Lilly USA, LLC
    • 16.11.1 Company Snapshot
    • 16.11.2 Company Overview
    • 16.11.3 Financial Analysis
      • 16.11.3.1 Net Revenue, 2021-2024
      • 16.11.3.2 R&D, 2021-2024
      • 16.11.3.3 Regional Market Shares, 2024
      • 16.11.3.4 Business Segment Market Shares, 2024
    • 16.11.4 Product Benchmarking
    • 16.11.5 SWOT Analysis
    • 16.11.6 Strategic Outlook
  • 16.12 F. Hoffmann-La Roche Ltd.
    • 16.12.1 Company Snapshot
    • 16.12.2 Company Overview
    • 16.12.3 Financial Analysis
      • 16.12.3.1 Net Revenue, 2021-2024
    • 16.12.4 Product Benchmarking
    • 16.12.5 SWOT Analysis
    • 16.12.6 Strategic Outlook
  • 16.13 GSK plc.
    • 16.13.1 Company Snapshot
    • 16.13.2 Company Overview
    • 16.13.3 Financial Analysis
      • 16.13.3.1 Net Revenue, 2021-2024
      • 16.13.3.2 R&D, 2021-2024
      • 16.13.3.3 Regional Market Shares, 2024
      • 16.13.3.4 Business Segment Market Shares, 2024
    • 16.13.4 Product Benchmarking
    • 16.13.5 SWOT Analysis
    • 16.13.6 Strategic Outlook
  • 16.14 Merck & Co., Inc.
    • 16.14.1 Company Snapshot
    • 16.14.2 Company Overview
    • 16.14.3 Financial Analysis
      • 16.14.3.1 Net Revenue, 2021-2024
      • 16.14.3.2 R&D, 2021-2024
      • 16.14.3.3 Regional Market Shares, 2024
      • 16.14.3.4 Business Segment Market Shares, 2024
    • 16.14.4 Product Benchmarking
    • 16.14.5 SWOT Analysis
    • 16.14.6 Strategic Outlook
  • 16.15 Novo Nordisk A/S
    • 16.15.1 Company Snapshot
    • 16.15.2 Company Overview
    • 16.15.3 Financial Analysis
      • 16.15.3.1 Net Revenue, 2021-2024
      • 16.15.3.2 R&D, 2021-2024
      • 16.15.3.3 Regional Market Shares, 2024
      • 16.15.3.4 Business Segment Market Shares, 2024
    • 16.15.4 Product Benchmarking
    • 16.15.5 SWOT Analysis
    • 16.15.6 Strategic Outlook
  • 16.16 Pfizer Inc.
    • 16.16.1 Company Snapshot
    • 16.16.2 Company Overview
    • 16.16.3 Financial Analysis
      • 16.16.3.1 Net Revenue, 2021-2024
      • 16.16.3.2 R&D, 2021-2024
      • 16.16.3.3 Regional Market Shares, 2024
      • 16.16.3.4 Business Segment Market Shares, 2024
    • 16.16.4 Product Benchmarking
    • 16.16.5 SWOT Analysis
    • 16.16.6 Strategic Outlook
  • 16.17 Sanofi
    • 16.17.1 Company Snapshot
    • 16.17.2 Company Overview
    • 16.17.3 Financial Analysis
      • 16.17.3.1 Net Revenue, 2021-2024
      • 16.17.3.2 R&D, 2021-2024
      • 16.17.3.3 Regional Market Shares, 2024
      • 16.17.3.4 Business Segment Market Shares, 2024
    • 16.17.4 Product Benchmarking
    • 16.17.5 SWOT Analysis
    • 16.17.6 Strategic Outlook
  • 16.18 Structure Therapeutics, Inc.
    • 16.18.1 Company Snapshot
    • 16.18.2 Company Overview
    • 16.18.3 Financial Analysis
      • 16.18.3.1 R&D, 2021-2024
    • 16.18.4 Product Benchmarking
    • 16.18.5 SWOT Analysis
    • 16.18.6 Strategic Outlook
  • 16.19 Takeda Pharmaceutical Company Limited.
    • 16.19.1 Company Snapshot
    • 16.19.2 Company Overview
    • 16.19.3 Financial Analysis
      • 16.19.3.1 Net Revenue, 2021-2024
      • 16.19.3.2 R&D, 2021-2024
      • 16.19.3.3 Regional Market Shares, 2024
    • 16.19.4 Product Benchmarking
    • 16.19.5 SWOT Analysis
    • 16.19.6 Strategic Outlook
  • 16.20 Zealand Pharma
    • 16.20.1 Company Snapshot
    • 16.20.2 Company Overview
    • 16.20.3 Financial Analysis
      • 16.20.3.1 Net Revenue, 2021-2024
      • 16.20.3.2 R&D, 2021-2024
      • 16.20.3.3 Regional Market Shares, 2024
    • 16.20.4 Product Benchmarking
    • 16.20.5 SWOT Analysis
    • 16.20.6 Strategic Outlook
  • 16.21 Zydus Lifesciences Limited
    • 16.21.1 Company Snapshot
    • 16.21.2 Company Overview
    • 16.21.3 Financial Analysis
      • 16.21.3.1 Net Revenue, 2021-2024
      • 16.21.3.2 R&D, 2021-2024
      • 16.21.3.3 Regional Market Shares, 2024
      • 16.21.3.4 Business Segment Market Shares, 2024
    • 16.21.4 Product Benchmarking
    • 16.21.5 SWOT Analysis
    • 16.21.6 Strategic Outlook

17. Conclusion and Recommendations

  • 17.1 Concluding Remarks from Visiongain
  • 17.2 Recommendations for Market Players
Show more
Product Code: PHA1380

List of Tables

  • Table 1 Anti-obesity Drugs Market Snapshot, 2026 & 2036 (US$ Billion, CAGR %)
  • Table 2 Anti-obesity Drugs Market: International Trade Tariff Impact Recovery Scenarios Snapshot
  • Table 3 Anti-obesity Drugs Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: V- Shaped Recovery Scenario
  • Table 4 Anti-obesity Drugs Market Forecast by Region 2026-2036 (US$ Billion,AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
  • Table 5 Anti-obesity Drugs Market Forecast by Region 2026-2036 (US$ Billion, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
  • Table 6 Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 7 Prescription Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 8 OTC Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 9 Anti-obesity Drugs Market by Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 10 Biologics Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 11 Small Molecules Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 12 Anti-obesity Drugs Market by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 13 Single-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 14 Dual-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 15 Tri-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 16 Anti-obesity Drugs Market by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 17 Centrally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 18 Peripherally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 19 Combined (Centrally and Peripherally Acting) Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 20 Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 21 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 22 Intravenous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 23 Subcutaneous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 24 Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 25 Hospital Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 26 Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 27 Online Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 28 Anti-obesity Drugs Market Forecast by Region, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 29 North America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 30 North America Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 31 North America Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 32 North America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 33 North America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 34 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 35 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 36 U.S. Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 37 Canada Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 38 Europe Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 39 Europe Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 40 Europe Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 41 Europe Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 42 Europe Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 43 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 44 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 45 Germany Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 46 France Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 47 UK Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 48 Italy Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 49 Spain Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 50 Russia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 51 Rest of Europe Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 52 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 53 Asia Pacific Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 54 Asia Pacific Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 55 Asia Pacific Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 56 Asia Pacific Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 57 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 58 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 59 Japan Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 60 China Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 61 India Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 62 Australia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 63 South Korea Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 64 Singapore Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 65 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 66 Latin America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 67 Latin America Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 68 Latin America Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 69 Latin America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 70 Latin America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 71 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 72 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 73 Brazil Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 74 Mexico Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 75 Argentina Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 76 Rest of Latin America Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 77 Middle East & Africa Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 78 Middle East & Africa Anti-obesity Drugs Market Drug Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 79 Middle East & Africa Anti-obesity Drugs Market Molecule Type, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 80 Middle East & Africa Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 81 Middle East & Africa Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 82 Middle East & Africa Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 83 Middle East & Africa Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR%, CAGR %)
  • Table 84 GCC Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 85 South Africa Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 86 Rest of MEA Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 87 Strategic Outlook
  • Table 88 Amgen Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 89 Amgen Inc.: Product Benchmarking
  • Table 90 Amgen Inc.: SWOT Analysis
  • Table 91 Amgen Inc.: Strategic Outlook
  • Table 92 AstraZeneca: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 AstraZeneca: Product Benchmarking
  • Table 94 AstraZeneca: SWOT Analysis
  • Table 95 AstraZeneca: Strategic Outlook
  • Table 96 Altimmune, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 Altimmune, Inc: Product Benchmarking
  • Table 98 Altimmune, Inc: SWOT Analysis
  • Table 99 Altimmune, Inc: Strategic Outlook
  • Table 100 Bayer AG: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 101 Bayer AG: Product Benchmarking
  • Table 102 Bayer AG: SWOT Analysis
  • Table 103 Bayer AG: Strategic Outlook
  • Table 104 Boerhinger Ingelheim International GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 105 Boerhinger Ingelheim International GmbH: Product Benchmarking
  • Table 106 Boerhinger Ingelheim International GmbH: SWOT Analysis
  • Table 107 Boerhinger Ingelheim International GmbH: Strategic Outlook
  • Table 108 CHEPLAPHARM Arzneimittel GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 109 CHEPLAPHARM Arzneimittel GmbH.: Product Benchmarking
  • Table 110 CHEPLAPHARM Arzneimittel GmbH: SWOT Analysis
  • Table 111 CHEPLAPHARM Arzneimittel GmbH.: Strategic Outlook
  • Table 112 Curaxx Pharmaceuticals LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Curaxx Pharmaceuticals LLC: Product Benchmarking
  • Table 114 Curaxx Pharmaceuticals LLC: SWOT Analysis
  • Table 115 Curaxx Pharmaceuticals LLC: Strategic Outlook
  • Table 116 Eisai Co., Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 117 Eisai Co., Ltd: Product Benchmarking
  • Table 118 Eisai Co., Ltd: SWOT Analysis
  • Table 119 Eisai Co., Ltd: Strategic Outlook
  • Table 120 Lilly USA, LLC: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 121 Lilly USA, LLC: Product Benchmarking
  • Table 122 Lilly USA, LLC: SWOT Analysis
  • Table 123 Lilly USA, LLC: Strategic Outlook
  • Table 124 F. Hoffmann-La Roche Ltd: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 125 F. Hoffmann-La Roche Ltd: Product Benchmarking
  • Table 126 F. Hoffmann-La Roche Ltd: SWOT Analysis
  • Table 127 F. Hoffmann-La Roche Ltd: Strategic Outlook
  • Table 128 GSK plc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 129 GSK plc.: Product Benchmarking
  • Table 130 GSK plc.: SWOT Analysis
  • Table 131 GSK plc.: Strategic Outlook
  • Table 132 Merck & Co., Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 133 Merck & Co., Inc.: Product Benchmarking
  • Table 134 Merck & Co., Inc.: SWOT Analysis
  • Table 135 Merck & Co., Inc. .: Strategic Outlook
  • Table 136 Novo Nordisk A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 137 Novo Nordisk A/S: Product Benchmarking
  • Table 138 Novo Nordisk A/S: SWOT Analysis
  • Table 139 Novo Nordisk A/S: Strategic Outlook
  • Table 140 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 141 Pfizer Inc.: Product Benchmarking
  • Table 142 Pfizer Inc.: SWOT Analysis
  • Table 143 Pfizer Inc.: Strategic Outlook
  • Table 144 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 145 Sanofi: Product Benchmarking
  • Table 146 Sanofi: SWOT Analysis
  • Table 147 Sanofi: Strategic Outlook
  • Table 148 Structure Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 149 Structure Therapeutics, Inc.: Product Benchmarking
  • Table 150 Structure Therapeutics, Inc.: SWOT Analysis
  • Table 151 Structure Therapeutics, Inc.: Strategic Outlook
  • Table 152 Takeda Pharmaceutical Company Limited: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 153 Takeda Pharmaceutical Company Limited: Product Benchmarking
  • Table 154 Takeda Pharmaceutical Company Limited.: SWOT Analysis
  • Table 155 Takeda Pharmaceutical Company Limited: Strategic Outlook
  • Table 156 Zealand Pharma A/S: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 1 Zealand Pharma A/S: Product Benchmarking
  • Table 157 Zealand Pharma A/S .: SWOT Analysis
  • Table 158 Zealand Pharma A/S : Strategic Outlook
  • Table 159 Zydus Lifesciences: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 160 Zydus Lifesciences Limited: Product Benchmarking
  • Table 161 Zydus Lifesciences Limited.: SWOT Analysis
  • Table 162 Zydus Lifesciences: Strategic Outlook

List of Figures

  • Figure 1 Anti-obesity Drugs Market Segmentation
  • Figure 2 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
  • Figure 3 Anti-obesity Drugs Market by Molecule Type: Market Attractiveness Index
  • Figure 4 Anti-obesity Drugs Market by Type of Agonist: Market Attractiveness Index
  • Figure 5 Anti-obesity Drugs Market by Action Pathway: Market Attractiveness Index
  • Figure 6 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
  • Figure 7 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
  • Figure 8 Anti-obesity Drugs Market Attractiveness Index by Region
  • Figure 9 Anti-obesity Drugs Market: Market Dynamics
  • Figure 10 Anti-obesity Drugs Market: Impact Analysis
  • Figure 11 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 12 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 13 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 14 Short Term & Long Term Planning
  • Figure 15 Impact of U.S. and China Trade War
  • Figure 16 Most Impacted Countries
  • Figure 17 Global Market Tariff Sensitivity and Margin Pressure Analysis
  • Figure 18 Anti-obesity Drugs Market: Porter's Five Forces Analysis
  • Figure 19 Anti-obesity Drugs Market: PEST Analysis
  • Figure 20 Anti-obesity Drugs Market by Drug Type: Market Attractiveness Index
  • Figure 21 Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 22 Anti-obesity Drugs Market Share Forecast by Drug Type, 2026, 2031, 2036 (%)
  • Figure 23 Prescription Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 24 Prescription Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 25 OTC Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 26 OTC Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 27 Anti-obesity Drugs Market by Molecule Type: Market Attractiveness Index
  • Figure 28 Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 29 Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026, 2031, 2036 (%)
  • Figure 30 Biologics Agonists Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 31 Biologics Agonists Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 32 Small Molecules Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 33 Small Molecules Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 34 Anti-obesity Drugs Market by Type of Agonist: Market Attractiveness Index
  • Figure 35 Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
  • Figure 36 Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026, 2031, 2036 (%)
  • Figure 37 Single-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 38 Single-Agonist Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 39 Dual-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 40 Dual-Agonist Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 41 Tri-Agonist Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 42 Tri-Agonist Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 43 Anti-obesity Drugs Market by Action Pathway: Market Attractiveness Index
  • Figure 44 Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
  • Figure 45 Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026, 2031, 2036 (%)
  • Figure 46 Centrally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 47 Centrally Acting Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 48 Peripherally Acting Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 49 Peripherally Acting Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 50 Combined (Centrally and Peripherally Acting) Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR%)
  • Figure 51 Combined (Centrally and Peripherally Acting) Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 52 Anti-obesity Drugs Market by Route of Administration: Market Attractiveness Index
  • Figure 53 Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 54 Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026, 2031, 2036 (%)
  • Figure 55 Oral Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 56 Oral Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 57 Intravenous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 58 Intravenous Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 59 Subcutaneous Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 60 Subcutaneous Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 61 Anti-obesity Drugs Market by Distribution Channel: Market Attractiveness Index
  • Figure 62 Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 63 Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026, 2031, 2036 (%)
  • Figure 64 Hospital Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 65 Hospital Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 66 Retail Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 67 Retail Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 68 Online Pharmacies Segment Market Forecast by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 69 Online Pharmacies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 70 Anti-obesity Drugs Market Forecast by Region 2026 and 2036 (Revenue, CAGR%)
  • Figure 71 Anti-obesity Drugs Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 72 Anti-obesity Drugs Market by Region, 2026-2036 (US$ Billion, AGR %)
  • Figure 73 North America Anti-obesity Drugs Market Attractiveness Index
  • Figure 74 North America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 75 North America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 76 North America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 77 North America Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 78 North America Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 79 North America Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 80 North America Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 81 North America Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
  • Figure 82 North America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
  • Figure 83 North America Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
  • Figure 84 North America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
  • Figure 85 North America Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
  • Figure 86 North America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 87 North America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 88 North America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 89 North America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
  • Figure 90 U.S. Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 91 Canada Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 92 Europe Anti-obesity Drugs Market Attractiveness Index
  • Figure 93 Europe Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 94 Europe Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 95 Europe Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 96 Europe Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 97 Europe Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 98 Europe Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 99 Europe Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 100 Europe Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
  • Figure 101 Europe Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
  • Figure 102 Europe Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
  • Figure 103 Europe Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
  • Figure 104 Europe Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
  • Figure 105 Europe Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 106 Europe Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 107 Europe Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 108 Europe Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
  • Figure 109 Germany Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 110 France Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 111 UK Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 112 Italy Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 113 Spain Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 114 Russia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 115 Rest of Europe Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 116 Asia Pacific Anti-obesity Drugs Market Attractiveness Index
  • Figure 117 Asia Pacific Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 118 Asia Pacific Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 119 Asia Pacific Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 120 Asia Pacific Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 121 Asia Pacific Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 122 Asia Pacific Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 123 Asia Pacific Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 124 Asia Pacific Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
  • Figure 125 Asia Pacific Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
  • Figure 126 Asia Pacific Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
  • Figure 127 Asia Pacific Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
  • Figure 128 Asia Pacific Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
  • Figure 129 Asia Pacific Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 130 Asia Pacific Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 131 Asia Pacific Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 132 Asia Pacific Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
  • Figure 133 Japan Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 134 China Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 135 India Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 136 Australia Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 137 South Korea Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 138 Singapore Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 139 Rest of Asia Pacific Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 140 Latin America Anti-obesity Drugs Market Attractiveness Index
  • Figure 141 Latin America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 142 Latin America Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 143 Latin America Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 144 Latin America Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 145 Latin America Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 146 Latin America Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 147 Latin America Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 148 Latin America Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
  • Figure 149 Latin America Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
  • Figure 150 Latin America Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
  • Figure 151 Latin America Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
  • Figure 152 Latin America Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
  • Figure 153 Latin America Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 154 Latin America Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 155 Latin America Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 156 Latin America Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
  • Figure 157 Brazil Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 158 Mexico Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 159 Argentina Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 160 Rest of Latin America Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 161 Middle East & Africa Anti-obesity Drugs Market Attractiveness Index
  • Figure 162 Middle East & Africa Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 163 Middle East & Africa Anti-obesity Drugs Market by Region, 2026, 2031 & 2036 (US$ Billion)
  • Figure 164 Middle East & Africa Anti-obesity Drugs Market Forecast by Country, 2026-2036 (US$ Billion, AGR %)
  • Figure 165 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 166 Middle East & Africa Anti-obesity Drugs Market Forecast by Drug Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 167 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Drug Type, 2026 & 2036 (%)
  • Figure 168 Middle East & Africa Anti-obesity Drugs Market Forecast by Molecule Type, 2026-2036 (US$ Billion, AGR %)
  • Figure 169 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Molecule Type, 2026 & 2036 (%)
  • Figure 170 Middle East & Africa Anti-obesity Drugs Market Forecast by Type of Agonist, 2026-2036 (US$ Billion, AGR %)
  • Figure 171 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Type of Agonist, 2026 & 2036 (%)
  • Figure 172 Middle East & Africa Anti-obesity Drugs Market Forecast by Action Pathway, 2026-2036 (US$ Billion, AGR %)
  • Figure 173 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Action Pathway, 2026 & 2036 (%)
  • Figure 174 Middle East & Africa Anti-obesity Drugs Market Forecast by Route of Administration, 2026-2036 (US$ Billion, AGR %)
  • Figure 175 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Route of Administration, 2026 & 2036 (%)
  • Figure 176 Middle East & Africa Anti-obesity Drugs Market Forecast by Distribution Channel, 2026-2036 (US$ Billion, AGR %)
  • Figure 177 Middle East & Africa Anti-obesity Drugs Market Share Forecast by Distribution Channel, 2026 & 2036 (%)
  • Figure 178 GCC Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 179 South Africa Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 180 Rest of MEA Anti-obesity Drugs Market Forecast, 2026-2036 (US$ Billion, AGR %)
  • Figure 181 Anti-obesity Drugs Market: Company Share/Ranking, 2026
  • Figure 182 Amgen Inc: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 183 Amgen Inc.: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 184 Amgen Inc.: Regional Market Shares, 2024
  • Figure 185 AstraZeneca: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 186 AstraZeneca.: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 187 AstraZeneca: Regional Market Shares, 2024
  • Figure 188 AstraZeneca: Business Segment Market Shares, 2024
  • Figure 189 Altimmune, Inc: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 190 Altimmune, Inc.: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 191 Bayer AG : Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 192 Bayer AG : R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 193 Bayer AG : Regional Market Shares, 2024
  • Figure 194 Bayer AG : Business Segment Market Shares, 2024
  • Figure 195 Boehringer Ingelheim International GmbH: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 196 Boehringer Ingelheim International GmbH: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 197 Boehringer Ingelheim International GmbH: Regional Market Shares, 2024
  • Figure 198 Boehringer Ingelheim International GmbH: Business Segment Market Shares, 2024
  • Figure 199 Eisai Co., Ltd: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 200 Eisai Co., Ltd: Regional Market Shares, 2024
  • Figure 201 Lilly USA, LLC: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 202 Lilly USA, LLC: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 203 Lilly USA, LLC: Regional Market Shares, 2024
  • Figure 204 Lilly USA, LLC: Business Segment Market Shares, 2024
  • Figure 205 F. Hoffmann-La Roche Ltd: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 206 GSK plc: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 207 GSK plc: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 208 GSK plc: Regional Market Shares, 2024
  • Figure 209 GSK plc: Business Segment Market Shares, 2024
  • Figure 210 Merck & Co., Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 211 Merck & Co., Inc.: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 212 Merck & Co., Inc.: Regional Market Shares, 2024
  • Figure 213 Merck & Co., Inc.: Business Segment Market Shares, 2024
  • Figure 214 Novo Nordisk A/S: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 215 Novo Nordisk A/S: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 216 Novo Nordisk A/S: Regional Market Shares, 2024
  • Figure 217 Novo Nordisk A/S.: Business Segment Market Shares, 2024
  • Figure 218 Pfizer Inc.: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 219 Pfizer Inc.: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 220 Pfizer Inc.: Regional Market Shares, 2024
  • Figure 221 Pfizer Inc.: Business Segment Market Shares, 2024
  • Figure 222 Sanofi: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 223 Sanofi: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 224 Sanofi: Regional Market Shares, 2024
  • Figure 225 Sanofi: Business Segment Market Shares, 2024
  • Figure 226 Structure Therapeutics, Inc.: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 227 Takeda Pharmaceutical Company Limited.: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 228 Takeda Pharmaceutical Company Limited.: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 229 Takeda Pharmaceutical Company Limited.: Regional Market Shares, 2024
  • Figure 230 Zealand Pharma A/S .: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 231 Zealand Pharma A/S : R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 232 Zealand Pharma A/S.: Regional Market Shares, 2024
  • Figure 233 Zydus Lifesciences Limited.: Net Revenue, 2021-2024 (US$ Million, AGR%)
  • Figure 234 Zydus Lifesciences Limited.: R&D, 2021-2024 (US$ Million, AGR%)
  • Figure 235 Zydus Lifesciences Limited.: Regional Market Shares, 2024
  • Figure 236 Zydus Lifesciences Limited.: Business Segment Market Shares, 2024
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!